Hotpennystocknews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angeles, CA -- (SBWIRE) -- 02/03/2014 -- Hotpennystocknews.com issues special report on - InterMune (ITMN),Corcept Therapeutics Inc. (NASDAQ:CORT),Geron Corporation (NASDAQ:GERN),Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
InterMune (ITMN) is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is marketed by InterMune in the EU and Canada as Esbriet and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune’s research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.
Shares of InterMune (ITMN) tumbled by more than 15% today, as the company is suffering from a possible trial data leak from a competitor's idiopathic pulmonary fibrosis drug, which successfully passed its phase 3 trials, and put up solid data. David points to one analyst from Summer Street who quickly came to InterMune's defense, saying that while the two drugs are technically competitors, patients would be cycled between them, given the nature of the IPF disease.
Click Here To know About ITMN, It’s Free.
Corcept Therapeutics Inc. (NASDAQ:CORT) is engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders.
CORT after breaking out on 28thJanuary’14 has been continuously rallying. The stock is trading way above its 20-Day and 50-Day EMA of $3.16 and $2.82 with RSI of 65.40. There has been price and volume action which has been observed in the stock as the stock is trading above its average volume of 0.54M.
CORT reported estimated net -revenue of $4.1M for the 2013Q4 and $10.4M for the full year. Its estimated cash & cash equivalents were $54.9M at year-end. The company’s audited-results will be available when Corcept Therapeutics Incorporated (CORT) files the Annual Report on the Form 10-K with the SEC. Corcept Therapeutics Incorporated (CORT) estimates that its 2014 net revenue will be in the $24M-$28M range.
Can CORT Show a Strong Recovery? Find out in This Research Report.
Geron Corporation (NASDAQ:GERN) develops therapeutic products for cancer that inhibit telomerase. Its product candidate include Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials.
GERN was a big mover last session, as the company saw its shares surge nearly 24% on the day. This significant rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $4.26 to $5.71 in the past one-month time frame, showed a pick-up yesterday at $5.35. The stock shot up on the company's announcement of the pricing of its common stock offering.
Should Investors Buy GERN Now? Free Sign Up Here For GERN Analyst Report.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors to address major therapeutic areas like cardiovascular & metabolic diseases.
ARNA investors can be a bit encouraged by the progress in weekly prescription sales so far in 2013, but to be honest, they are not seeing a record setting pace as yet. Typically the first half of the year is the strongest season for weight-loss products, and thus, good week-over-week numbers should be expected even without an impedes of television ads. In the coming days or weeks, they should see television advertising begin, and that could be just the fuel needed to get the street and active traders behind the prescription weight loss story.
Click here to receive FREE breaking news email alerts for ARNA.
Neither Hotpennystocknews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by Hotpennystocknews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.Hotpennystocknews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Hotpennystocknews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in.
Read Full disclaimer at:http://www.hotpennystocknews.com/disclaimer.php
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)